Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cord blood-derived gamma delta T cells + cord blood-derived natural killer cells
- Development stage
- Preclinical
- Lead developer
- CytoMed Therapeutics China
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This combination cell therapy, developed by LongevityBank, utilizes gamma delta (γδ) T cells and natural killer (NK) cells derived from umbilical cord blood for the treatment of various cancer types. These specific immune cell populations are characterized by their innate ability to recognize and eliminate tumor cells in a non-MHC-restricted manner, which potentially allows for 'off-the-shelf' therapeutic applications with a reduced risk of graft-versus-host disease (GvHD) compared to conventional αβ T-cell therapies. The therapy leverages the robust cytotoxic activity of both γδ T cells and NK cells to target multiple tumor types through cell-mediated cytotoxicity.
- Other names
- gamma delta T cellsgamma-delta T cellsNK cellscord blood-derived gamma delta T cellscord blood-derived NK cellscord blood-derived γδ T cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)BTN2A1 (Butyrophilin subfamily 2 member A1)NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)
Beyond the preview
Go deeper on cord blood-derived gamma delta T cells + cord blood-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cord blood-derived gamma delta T cells + cord blood-derived natural killer cells.